David I Fudman
Overview
Explore the profile of David I Fudman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fudman D, McConnell R, Ha C, Singh S
Clin Gastroenterol Hepatol
. 2024 Aug;
23(3):454-468.
PMID: 39147217
The therapeutic armamentarium for management of inflammatory bowel diseases has expanded dramatically in the last 5 years, with the introduction of several medications with different mechanisms of action. These include...
2.
Yin J, El-Najjar Y, Cordova N, Touma M, Nguyen N, Boktor M, et al.
Inflamm Bowel Dis
. 2024 May;
30(10):1914-1916.
PMID: 38767984
No abstract available.
3.
Yin J, Balachandar N, Karamchandani D, Vemulapalli R, Fudman D
Gastroenterol Rep (Oxf)
. 2024 Apr;
12:goae013.
PMID: 38566848
No abstract available.
4.
5.
Schroeder M, Tan S, Touma M, Basit M, Fudman D
Inflamm Bowel Dis
. 2023 Mar;
29(11):1837-1841.
PMID: 36866408
No abstract available.
6.
Llano E, Shrestha S, Burstein E, Boktor M, Fudman D
Crohns Colitis 360
. 2023 Feb;
3(3):otab030.
PMID: 36776641
Background: Combining advanced therapies may improve outcomes in inflammatory bowel disease (IBD), but there are little data on the effectiveness and safety of this approach. Methods: We examined outcomes of...
7.
Holmer A, Luo J, Russ K, Park S, Yang J, Ertem F, et al.
Clin Gastroenterol Hepatol
. 2023 Jan;
21(6):1598-1606.e5.
PMID: 36642291
Background & Aims: Safety of biologic agents is a key consideration in patients with inflammatory bowel disease (IBD) and active or recent cancer. We compared the safety of tumor necrosis...
8.
Gu P, Clifford E, Gilman A, Chang C, Moss E, Fudman D, et al.
Pathophysiology
. 2022 Jul;
29(3):383-393.
PMID: 35893600
Low socioeconomic status (SES) is associated with greater morbidity and increased healthcare resource utilization (HRU) in IBD. We examined whether a financial assistance program (FAP) to improve healthcare access affected...
9.
Alayo Q, Fenster M, Altayar O, Glassner K, Llano E, Clark-Snustad K, et al.
Crohns Colitis 360
. 2022 Mar;
4(1):otac002.
PMID: 35310082
Background: Combining biologics and small molecules could potentially overcome the plateau of drug efficacy in inflammatory bowel disease (IBD). We conducted a systematic review and meta-analysis to assess the safety...
10.
Fudman D, Singal A, Cooper M, Lee M, Murphy C
Clin Gastroenterol Hepatol
. 2021 Nov;
20(7):1508-1515.
PMID: 34839039
Background And Aims: The use of forceps for removal of nondiminutive polyps is associated with incomplete resection compared with snare polypectomy. However, few studies have characterized the frequency of forceps...